Loading…
Abrdn Life Sciences Investors is projected to rise to $22.95 by 2027, a +31% move from its current price of $17.53. HQL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $17.34 | $17.53 | $17.72 | 0.00% |
| May 30 | $17.27 | $17.53 | $17.80 | +0.01% |
| May 31 | $17.21 | $17.53 | $17.86 | +0.01% |
| Jun 1 | $17.16 | $17.53 | $17.91 | +0.01% |
| Jun 2 | $17.12 | $17.53 | $17.95 | +0.01% |
| Jun 3 | $17.08 | $17.53 | $18.00 | +0.02% |
| Jun 4 | $17.05 | $17.53 | $18.03 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.05 | $17.53 | $18.03 | +0.02% |
| Week 2 | $16.85 | $17.54 | $18.25 | +0.04% |
| Week 3 | $16.70 | $17.54 | $18.42 | +0.06% |
| Week 4 | $16.58 | $17.54 | $18.56 | +0.08% |
| Week 5 | $16.48 | $17.55 | $18.69 | +0.10% |
| Week 6 | $16.38 | $17.55 | $18.80 | +0.11% |
| Week 7 | $16.29 | $17.55 | $18.91 | +0.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index.
Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Abrdn Life Sciences Investors (HQL) is currently priced at $17.19 with a market capitalization of $522.71M and a rank of 3011. The asset trades in a landscape defined by small-cap growth exposure within the life sciences space.
The multi-year forecast presents a bullish outlook, with the average price rising from $17.19 in 2026 to $150.33 by 2050 and a maximum forecast of $246.00 in 2050. The predicted ROIs rise from 0% in 2026 to as high as 774.5% by 2050, underscoring substantial long-run upside potential according to the provided projections.
A major floor 9.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 3.9% above — a clean break opens room to run.
A major ceiling 6.5% above — clearing it would confirm fresh momentum.
Key HQL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HQL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.39 | Buy | $17.45 | Buy |
| MA 10 | $17.62 | Sell | $17.55 | Sell |
| MA 20 | $17.74 | Sell | $17.61 | Sell |
| MA 50 | $17.31 | Buy | $17.42 | Buy |
| MA 100 | $17.06 | Buy | $17.08 | Buy |
| MA 200 | $16.44 | Buy | $16.39 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.85 | Neutral |
| Stoch RSI (14) | 33.11 | Neutral |
| CCI (20) | -47.88 | Neutral |
| Williams %R (14) | -66.34 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -3.63 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 33.66 | Neutral |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 40.62 | Neutral |
| Momentum (10) | -0.56 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 17.23 | Buy |
| ADX (14) | 15.58 | Neutral |
| ATR (14) | 0.18 | Info |
The near-term technical picture is bullish. The RSI(14) is 40, with the 50-day simple moving average at $17.27 and the 200-day simple moving average at $16.40.
Support stands at $17.19 and resistance at $18.22. The 30-day range is $15.99 to $18.48, highlighting a tight price corridor around the current level. Annualized volatility is 20%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.87 | $17.53 | $24.34 | 0% | Neutral | |
| $18.75 | $22.95 | $29.41 | +31% | Bullish | |
| $19.04 | $23.73 | $31.20 | +35% | Bullish | |
| $21.63 | $27.37 | $36.73 | +56% | Bullish | |
| $23.27 | $29.83 | $40.75 | +70% | Bullish | |
| $25.01 | $32.45 | $45.02 | +85% | Bullish | |
| $31.50 | $41.34 | $58.15 | +136% | Bullish | |
| $34.24 | $45.39 | $64.67 | +159% | Bullish | |
| $36.36 | $48.69 | $70.19 | +178% | Bullish | |
| $39.41 | $53.26 | $77.63 | +204% | Bullish | |
| $58.58 | $82.57 | $126.07 | +371% | Bullish | |
| $108.33 | $163.74 | $267.92 | +834% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $15.87 | $17.53 | $20.56 | +0.00% |
| June 2026 | $15.09 | $17.61 | $20.94 | +0.44% |
| July 2026 | $14.98 | $17.57 | $21.10 | -0.19% |
| August 2026 | $15.43 | $18.19 | $22.00 | +3.51% |
| September 2026 | $15.80 | $18.69 | $22.73 | +2.73% |
| October 2026 | $15.74 | $18.68 | $22.84 | -0.03% |
| November 2026 | $15.97 | $19.01 | $23.36 | +1.79% |
| December 2026 | $16.52 | $19.72 | $24.34 | +3.73% |
Click any year to see its month-by-month HQL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, HQL is projected to trade between $15.87 and $24.34, averaging $17.53 — a potential gain of 0% from today's $17.53. Price action looks broadly range-bound.
Abrdn Life Sciences Investors's 2027 outlook centres on $22.95, within a $18.75 to $29.41 range. That is up +31% on the projected 2026 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, HQL could reach as high as $31.20, with a base case around $23.73 and support toward $19.04 — roughly +35% from $17.53. Momentum favours further upside here.
Expect HQL to range from $21.63 to $36.73 through 2029. The $27.37 average target implies a +56% move from current prices. That is up +15% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The HQL price prediction for 2030 points to an average of $29.83 (low $23.27, high $40.75) — a potential gain of +70% on today's $17.53. Momentum favours further upside here.
In 2031, HQL is projected to trade between $25.01 and $45.02, averaging $32.45 — a potential gain of +85% from today's $17.53. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Abrdn Life Sciences Investors's 2032 outlook centres on $41.34, within a $31.50 to $58.15 range. That is up +27% on the projected 2031 average. That marks a +136% change versus current levels. Momentum favours further upside here.
By 2033, HQL could reach as high as $64.67, with a base case around $45.39 and support toward $34.24 — roughly +159% from $17.53. Buyers look set to stay in control over this stretch.
Expect HQL to range from $36.36 to $70.19 through 2034. The $48.69 average target implies a +178% move from current prices. That is up +7% on the projected 2033 average. Momentum favours further upside here.
The HQL price prediction for 2035 points to an average of $53.26 (low $39.41, high $77.63) — a potential gain of +204% on today's $17.53. Buyers look set to stay in control over this stretch.
In 2040, HQL is projected to trade between $58.58 and $126.07, averaging $82.57 — a potential gain of +371% from today's $17.53. That is up +55% on the projected 2035 average. Momentum favours further upside here.
Abrdn Life Sciences Investors's 2050 outlook centres on $163.74, within a $108.33 to $267.92 range. That is up +98% on the projected 2040 average. That marks a +834% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in HQL today (≈ 57.045066 HQL) could be worth
$9,340.32
+$8,340.32 (+834%) by 2050 · US Dollar
Based on the average projected HQL price of $163.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HQLwould be worth at today's price.
$1,000 invested in HQL on May 27, 2025 (≈ 80.971657 HQL) would be worth
$1,419.43
+$419.43 (+41.9%) today · 1.42× · US Dollar
Based on a HQL entry price of $12.35 vs. today's $17.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.66 | $992.64 | -0.7% |
| 1 month ago | $17.56 | $998.29 | -0.2% |
| 3 months ago | $16.64 | $1,053.49 | +5.3% |
| 6 months ago | $17.67 | $992.08 | -0.8% |
| 1 year ago | $12.35 | $1,419.43 | +41.9% |
| All time (5.0y) ago | $19.85 | $883.12 | -11.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HQL forecast.
Our base-case forecast reaches $35.00 around 2032.
Implied market cap at $35.00: $1.06B
The multi-year forecast points to a bullish trajectory with meaningful upside across the horizon. By 2030 the average price is projected to $28.49 with a min of $22.21 and a max of $38.92, delivering a 65.7% ROI and bullish sentiment.
Forecasts continue to lift the price path through 2035 and beyond, with 2040 showing an average of $76.96 and a max of $117.52 (ROI 347.7%), and 2050 projecting an average of $150.33 with a max of $246.00 (ROI 774.5%). The long-run outlook is clearly bullish, though these are estimates and not guarantees. Risks and uncertainties are inherent in any forecast, and outcomes may differ from these projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $28.49 with a min of $22.21 and a max of $38.92. The projected ROI is 65.7% and the sentiment is BULLISH.
The forecast data indicate a bullish sentiment across many years, with the average price rising from $17.19 in 2026 to $150.33 in 2050 and a maximum forecast of $246.00 in 2050. The implied ROIs reach as high as 774.5% by 2050. These are estimates and not guarantees.
Yes. The max forecast price reaches $117.52 in 2040 and $246.00 in 2050, well above $100. The 2040 max is $117.52 and 2050 max is $246.00.
The current price is $17.19 and the market cap is $522.71M.
The 30-day range is $15.99 to $18.48. Near-term support is $17.19 and resistance is $18.22. RSI(14) is 40, SMA(50) is $17.27, SMA(200) is $16.40, and annualized volatility is 20%.
Abrdn Life Sciences Investors Community Discussion
0Share your Abrdn Life Sciences Investors price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.